Latest news with #Cushing
Indian Express
6 days ago
- Health
- Indian Express
Are you overfeeding your pet? Veterinarian details the mistakes pet parents make that lead to obesity
Overweight pets are no longer a rare sight. From chunky cats struggling to groom themselves to dogs that pant heavily after a short walk, pet obesity has become a growing concern today. Research from Royal Canin indicates that approximately 40% of adult cats and dogs worldwide are classified as overweight or obese. Purina Institute, in its report, adds, 'Worldwide, studies estimate that up to 63% of pet cats and 59.3% of pet dogs are overweight or obese.' This puts them at risk for serious health issues including joint pain, diabetes, heart disease, and a shortened lifespan. While it's easy to dismiss a pudgy pet as 'cute' or 'well-fed,' experts warn that this trend is often the result of human behaviour. Dr Deepraj Prajapati, senior veterinarian at RD Pet Hospital Ambedkar Nagar, tells 'One of the most common mistakes is equating food with affection. Many pet parents show love by offering extra treats or human food, unaware that even small indulgences can lead to calorie overload in animals. Another issue is misjudging appropriate portion size, owners often rely on visual estimation or outdated feeding guidelines rather than tailored advice from a vet.' Lack of physical activity is another factor, he states. In urban households, especially, pets may not get enough structured play or walks, and their energy expenditure is significantly lower than what their diet accounts for. Weight gain can creep in slowly, and because owners see their pets daily, they may not recognise the changes until the issue becomes severe. Commercial pet foods and treats can play a significant role in weight gain, particularly if feeding instructions aren't interpreted correctly. 'Many of these products market themselves as 'healthy' or 'nutritionally complete,' but the portion sizes recommended are often based on ideal conditions—not taking into account a pet's age, activity level, or breed,' says Dr Prajapati. He adds that treats are another overlooked source of excess calories. Some treats, even in small quantities, can add up to 15-20% of a pet's daily calorie needs. And because they're marketed as supplements or rewards, they're often not factored into daily meal planning. To avoid confusion, Dr Prajapati advises, it's best for pet parents to work with a vet to determine accurate portion sizes and understand label claims critically. Caloric density and ingredient quality vary widely between brands, and what works for one animal may not be suitable for another. In many cases, obesity in pets can be reversed through consistent dietary changes, increased physical activity, and ongoing monitoring. Dr Prajapati stresses, 'However, it requires a committed and gradual approach. Crash diets or sudden exercise routines can be harmful, especially in older pets or those with underlying conditions.' That said, there are situations where medical intervention is necessary. Dr Prajapati explains, 'Hormonal disorders like hypothyroidism or Cushing's disease can contribute to weight gain and make weight loss difficult without treatment. In such cases, medication, therapeutic diets, and regular veterinary check-ups become essential components of the weight management plan.' The goal is to create a sustainable routine that supports the pet's long-term health rather than focusing on short-term results.
The Standard
13-06-2025
- Business
- The Standard
Oil jumps 13 percent as Israel strikes Iran, rattling investors
Crude oil storage tanks are seen from above at the Cushing oil hub, in Cushing, Oklahoma, March 24, 2016. REUTERS
Cision Canada
05-06-2025
- Health
- Cision Canada
Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders
WESTBROOK, Maine, June 5, 2025 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst ® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care. Addison's disease, often called "the great pretender," is a life-threatening condition caused by low cortisol and is difficult to diagnose due to its common and nonspecific clinical signs that can resemble those of other illnesses, such as gastroenteritis or kidney disease. Early detection is critical, as timely treatment can be lifesaving. Cushing's syndrome, driven by excess cortisol, is a common endocrine disorder in older dogs, and certain breeds are at an increased risk. Cushing's syndrome requires long-term management, and if left untreated, it can significantly diminish quality of life. IDEXX's Catalyst Cortisol Test enables veterinarians to confidently and accurately diagnose or rule out Addison's disease and Cushing's syndrome during the patient visit, allowing for immediate treatment or adjustments to ongoing care management. This workflow efficiency continues throughout the patient journey with monitoring capabilities that enable tailored treatment adjustments, improving long-term care for patients with Cushing's syndrome. "The Catalyst Cortisol Test is an accurate and highly requested test that addresses a critical need for our customers and equips veterinarians with built-in results interpretation for prompt action, supporting better health outcomes for dogs," said Jay Mazelsky, President and Chief Executive Officer of IDEXX. "Continuing to expand the Catalyst platform reinforces our Technology for Life promise, offering our customers solutions that advance in capabilities over time to expand clinical insights and care delivery at the point-of-care." The IDEXX Catalyst Cortisol Test features: Accuracy: Provides quantitative results in-clinic that align with IDEXX Reference Laboratories, enabling veterinarians to confidently diagnose or rule out Addison's disease and Cushing's syndrome. Interpretive guidance: Integrates with the IDEXX Vetlab ® Station and VetConnect ® PLUS, providing results-specific interpretation in real-time during the patient visit. Efficiency: The Catalyst Cortisol Test's load-and-go workflow can run alone or with additional chemistry tests using a single sample for comprehensive diagnostic insights into patient health status. This workflow saves hands-on sample preparation time for veterinary technicians and ensures repeatable results. "A reliable in-house test is game-changing—it enables faster diagnosis and treatment of a life-threatening Addisonian crisis in dogs," said Patty Lathan, VMD, MS, DACVIM (SAIM).* "Additionally, by delivering accurate results during the visit, it supports timely care and streamlines daily workflows for busy veterinary teams." The Catalyst Cortisol Test will be available in the U.S. and Canada at the end of July 2025, with a global rollout to the installed base of more than 75,000 Catalyst chemistry analyzers expected to start in the third quarter of 2025. For more information, visit the IDEXX Catalyst test menu web page. About IDEXX IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: Note Regarding Forward-Looking Statements This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at and via IDEXX's website at
Globe and Mail
04-06-2025
- Business
- Globe and Mail
Is ExxonMobil's Plan for $35 Oil Breakeven Going to be a Game Changer?
Exxon Mobil Corporation XOM mentioned in its recent earnings call that it plans to lower its breakeven costs to $35 per barrel by 2027 and $30 per barrel by 2030. Now, the billion-dollar question lies with the investors: To what extent will this lower breakeven, if achieved, aid XOM? This is a realistic question that should arise in every investor's mind since the integrated energy giant derives the lion's share of its earnings from its upstream business. The no-brainer answer is that this level of low breakeven costs will be highly beneficial for XOM's bottom line, especially from its upstream business. In other words, ExxonMobil will remain profitable even if crude oil prices drop significantly and stand to earn substantially more when prices climb. To add to that, even during most months of 2020, when energy demand collapsed due to the COVID-19 pandemic, ExxonMobil's upstream operations could have been profitable if its breakeven costs had been $30 per barrel. Per data from the U.S. Energy Information Administration, the Cushing, OK, WTI Spot prices for March, April and May were only below the $30 per barrel mark. Thus, there is no doubt that this development, if achieved, is going to be a game changer for ExxonMobil. Other Upstream Firms With Low Breakeven Costs: CVX, EOG According to Statista, a leading platform for data collection and visualization, the breakeven price in the Permian, especially in the Delaware and Midland sub-basins, is well below $40 per barrel. Hence, companies operating in the Permian, like Chevron Corporation CVX and EOG Resources Inc. EOG, are experiencing low breakeven prices. In 2024, CVX conducted 80% of its development activities in the Delaware basin. Chevron plans to increase the development program in the Delaware basin to 85% this year. This simplifies CVX's strong focus on low breakeven-cost operations to maximize its profit. In its recent earnings call, EOG said that it could easily handle all its planned spending for this year, even if oil prices trade in the low $50 per barrel. That means that to remain financially healthy, EOG does not need high oil prices. XOM's Price Performance, Valuation & Estimates Shares of ExxonMobil have declined 4.4% over the past year, outpacing the 6.3% fall of the composite stocks belonging to the industry. From a valuation standpoint, XOM trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 6.45x. This is above the broader industry average of 4.05X. The Zacks Consensus Estimate for ExxonMobil's 2025 earnings has been revised downward over the past seven days. XOM currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report EOG Resources, Inc. (EOG): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Associated Press
03-06-2025
- Business
- Associated Press
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Jun 3, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. 'We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achievements have positioned us to take the next bold step in our journey of growth and transformation. We are excited to share our vision for the future—one that builds on our successes, leverages our capabilities, and propels us toward making an even greater impact delivering meaningful solutions for patients,' said John Shannon, Chief Executive Officer. Path to Long Term Value Creation Financial Guidance & Long-range Outlook 2025 Analyst and Investor Day Event Details The Company's first in-person and virtual analyst and investor day will be in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EDT. To access the live webcast of the event, please use this link: A replay of the webcast, along with the related presentation materials, will be available on the 'Events & Presentations' section of the Company's Investor Relations website following the conclusion of the event. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used during radiology exams as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including statements regarding financial guidance for 2025, including its expected total revenue and commitment to remaining adjusted EBITDA positive, the outlook for 2030 and outlook for 2035 and beyond, including statements regarding total revenue, product growth, annual net revenue expected for Recorlev® and XP-8121, the market and therapeutic potential of its products and product candidates, including Recorlev and XP-8121, the ability to continue to demonstrate rapid revenue growth, sustained momentum across the portfolio and maintain disciplined execution of the Company's growth strategy, the beneficial impact on the lives of patients, including XP-8121's potential to transform the treatment landscape for millions living with hypothyroidism, capital management enabling the self-funding of both near and long-term growth, and other statements containing the words 'will,' 'would,' 'continue,' 'expect,' 'should,' 'anticipate,' 'new,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris' experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris' actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its collaborators' ability to protect its intellectual property and proprietary technology, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs, and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris' filings, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. View source version on CONTACT: Xeris Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications [email protected] KEYWORD: ILLINOIS NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: OTHER HEALTH RESEARCH MANAGED CARE GENERAL HEALTH PHARMACEUTICAL MEDICAL DEVICES CLINICAL TRIALS SCIENCE BIOTECHNOLOGY MEDICAL SUPPLIES OTHER SCIENCE HEALTH SOURCE: Xeris Biopharma Holdings, Inc. Copyright Business Wire 2025. PUB: 06/03/2025 07:30 AM/DISC: 06/03/2025 07:31 AM
